# Kylie Shackleton

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kylie-shackleton/

## Facts

| Field | Value |
| --- | --- |
| Citations | 608 |
| Field | Cancer Treatment and Pharmacology |
| h-index | 9 |
| i10-index | 9 |
| OpenAlex ID | https://openalex.org/A5036785268 |
| Works | 36 |

## Researcher papers

- [Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers](https://scholariq.org/papers/interim-results-from-the-impact-study-evidence-for-prostate-specific-antigen/)
- [A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer](https://scholariq.org/papers/a-phase-ib-dose-escalation-and-expansion-study-of-the-bcl2-inhibitor-venetoclax/)
- [A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study](https://scholariq.org/papers/a-prospective-prostate-cancer-screening-programme-for-men-with-pathogenic/)
- [Exploring Australian regional cancer patients’ experiences of clinical trial participation via telehealth](https://scholariq.org/papers/exploring-australian-regional-cancer-patients-experiences-of-clinical-trial/)
- [Tumour morphology predicts PALB2 germline mutation status](https://scholariq.org/papers/tumour-morphology-predicts-palb2-germline-mutation-status/)
- [Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition](https://scholariq.org/papers/prostate-specific-antigen-velocity-in-a-prospective-prostate-cancer-screening/)
- [The incidence of PALB2 c.3113G>A in women with a strong family history of breast and ovarian cancer attending familial cancer centres in Australia](https://scholariq.org/papers/the-incidence-of-palb2-c-3113g-and-gt-a-in-women-with-a-strong-family-history-of/)
- [Safety and efficacy of the BCL2 inhibitor venetoclax in estrogen receptor (ER) and BCL2-positive metastatic breast cancer: The mBEP study.](https://scholariq.org/papers/safety-and-efficacy-of-the-bcl2-inhibitor-venetoclax-in-estrogen-receptor-er-and/)
- [Patient communication and experiences in cancer clinical drug trials: a mixed-method study at a specialist clinical trials unit](https://scholariq.org/papers/patient-communication-and-experiences-in-cancer-clinical-drug-trials-a-mixed/)
- [Patient and medical barriers preclude uptake of tamoxifen preventative therapy in women with a strong family history](https://scholariq.org/papers/patient-and-medical-barriers-preclude-uptake-of-tamoxifen-preventative-therapy/)

## Researcher topics

- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.